#WCLC24 roundup: ArriVent thinks its drug can fill Tagrisso's gaps; Boehringer, Bayer's data in HER2-mutated lung cancer
Aside from Summit Therapeutics’ shocking win over Merck’s Keytruda, here’s what else you need to know from the World Conference on Lung …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
